Ovarian cancer survival by stage, histotype, and pre-diagnostic lifestyle factors, in the prospective UK Million Women Study

Gaitskell, Kezia; Hermon, C; Barnes, Isobel; Pirie, Kirstin; Floud, Sarah; Green, Jane; Beral, Valerie; Reeves, Gillian

doi:10.1016/j.canep.2021.102074

Cited by 39 publications

(34 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the literature, even when adjusting for other factors, the tumor histotype is widely associated with survival, partly due to different responsiveness to treatment. A SEER data analysis conducted in 2019 reported low-grade serous and endometrioid OC to have the most favorable outcomes, independently of stage, and reported definitely higher mortality for carcinosarcoma and distant-stage mucinous and clear cell OC [ 56 , 57 ]. In the past there has been some inconsistency among trials on histotype-specific survival, however, such studies presented many limitations.…”

Section: Resultsmentioning

confidence: 99%

Predicting Response to Anthracyclines in Ovarian Cancer

Ferrero

Borghese²,

Restaino

et al. 2022

IJERPH

View full text Add to dashboard Cite

(1) Background: Anthracyclines are intriguing drugs, representing one of the cornerstones of both first and subsequent-lines of chemotherapy in ovarian cancer (OC). Their efficacy and mechanisms of action are related to the hot topics of OC clinical research, such as BRCA status and immunotherapy. Prediction of response to anthracyclines is challenging and no markers can predict certain therapeutic success. The current narrative review provides a summary of the clinical and biological mechanisms involved in the response to anthracyclines. (2) Methods: A MEDLINE search of the literature was performed, focusing on papers published in the last two decades. (3) Results and Conclusions: BRCA mutated tumors seem to show a higher response to anthracyclines compared to sporadic tumors and the severity of hand–foot syndrome and mucositis may be a predictive marker of PLD efficacy. CA125 can be a misleading marker of clinical response during treatment with anthracyclines, the response of which also appears to depend on OC histology. Immunochemistry, in particular HER-2 expression, could be of some help in predicting the response to such drugs, and high levels of mutated p53 appear after exposure to anthracyclines and impair their antitumor effect. Finally, organoids from OC are promising for drug testing and prediction of response to chemotherapy.

show abstract

Section: Resultsmentioning

confidence: 99%

Predicting Response to Anthracyclines in Ovarian Cancer

Ferrero

Borghese²,

Restaino

et al. 2022

IJERPH

View full text Add to dashboard Cite

show abstract

“…Expression of MUC1 in ovarian cancer. Ovarian cancer is one of the most lethal gynaecological malignancies, and the prognosis of affected patients is often poor due to its inconspicuous early symptoms and its tendency to invade surrounding organs (36). The MUC1 oncogene is involved in the progression, metastasis and drug resistance of ovarian cancer cells (37).…”

Section: Expression Of Muc1 In Breast Cancermentioning

confidence: 99%

Expression of MUC1 in different tumours and its clinical significance (Review)

Lan

Tai

2022

Mol Clin Oncol

View full text Add to dashboard Cite

Mucin 1 (MUC1) was the first discovered transmembrane protein of the mucin family; it normally covers epithelial cells of the mucous membrane, providing lubrication and protection. However, aberrant expression of MUC1 is involved in cancer development, invasion and metastasis. It has been reported that MUC1 upregulation is highly associated with the progression of different epithelial cancer types, such as lung, liver, pancreatic and breast cancer. Therefore, MUC1 can be used as a specific marker and a target for immunotherapy in clinical applications, and the detection of MUC1 expression levels can be used to diagnose the occurrence, metastasis, prognosis and recurrence of cancer. The present review summarizes the abnormal expression of MUC1 in different tumours and discusses its clinical significance, thereby highlighting the potential diagnostic and therapeutic significance of MUC1 in cancer.

show abstract

“…The upper chamber was coated with 80 μL mixture composed of Matrigel (Corning, Wiesbaden, Germany) and culture medium (1:7). SKOV3 cells were seeded into the upper chamber with serum-free medium with the amount of 1×10 5 . Subsequently, 600 μl complete medium was added to the lower chamber.…”

Section: Transwell Assaymentioning

confidence: 99%

“…The drift of ovarian cancer mortality was 0.76% per year from 1990 to 2019 in China, which exhibited a sustained growth trend as well [4]. Present prognostic models for ovarian cancer survival mainly focus on clinico-pathological parameters like age at diagnosis, tumor stage and histological subtype [5]. Nonetheless, ovarian cancer possesses complex cell-cell interactions and molecular regulation mechanisms, thus qualitative predictors are limited by their e ciency and consistency among patients [6].…”

Section: Introductionmentioning

confidence: 99%

Transcriptome profiling in ovarian cancer cells treated with platelets reveals that TGFBI as a novel prognostic indicator

Wang

Guo

2022

Preprint

View full text Add to dashboard Cite

Background Ovarian cancer is a gynecologic malignancy with poor prognosis. Present prognostic models for ovarian cancer focus on clinico-pathological parameters, quantifiable prognostic biomarkers at molecular level are urgently needed. Platelets contribute to ovarian cancer progression, thus we aimed to search for new predictors in platelet-treated ovarian cancer cells. Methods Microarrays analysis was done with platelet-treated SKOV3 cells and controls (4 replicates in each group). Studies on ovarian cancer cells co-incubated with platelets were searched in the Gene Expression Omnibus (GEO) database. Differentially expressed genes (DEGs) were identified by R language. Gene Ontology (GO) analysis and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment were conducted using online software Metascape. Venn diagram was generated to present common DEGs. Candidate genes were determined by protein-protein interaction (PPI) network, Cox proportional hazards model and Kaplan-Meier analysis. The functions of candidate genes were predicted using data from TCGA by R software, and validated by in vitro experiments. Results One dataset (GSE155546) met the inclusion criteria and were analyzed with our microarray data. A total of 4553 mRNAs were differentially expressed between the two groups from our own data, whereas 260 genes exhibited significantly differential expression in GSE155546. DEGs involved in extracellular matrix (ECM) organization and system development were found in both datasets. There were 88 overlapping genes between the two datasets. TGFBI was proved to be an independent adverse factor for ovarian cancer. In addition, high expression of AFT3 and CXCL1 showed worse prognosis in ovarian cancer, while IGFBP7 behaved as a protective predictor. Only increased expression of TGFBI led to significant decrease of overall survival (OS), progression-free survival (PFS) and post-progression survival (PPS), therefore TGFBI was selected as the candidate gene. Functionally, TGFBI was predicted to be significantly correlated with epithelial mesenchymal transition (EMT) markers, degradation of ECM, collagen formation and ECM-related genes. In vitro experiments demonstrated that TGFBI could affect the migration and invasiveness of ovarian cancer cells by regulation E-cadherin, Vimentin, N-cadherin and MMP2. Conclusion We found TGFBI as a novel prognostic indicator using platelet-treated ovarian cancer model. Functionally, TGFBI could promote ovarian cancer progression by EMT induction and ECM remodeling.

show abstract

Ovarian cancer survival by stage, histotype, and pre-diagnostic lifestyle factors, in the prospective UK Million Women Study

Cited by 39 publications

References 32 publications

Predicting Response to Anthracyclines in Ovarian Cancer

Predicting Response to Anthracyclines in Ovarian Cancer

Expression of MUC1 in different tumours and its clinical significance (Review)

Transcriptome profiling in ovarian cancer cells treated with platelets reveals that TGFBI as a novel prognostic indicator

Contact Info

Product

Resources

About